Prescription stimulants in individuals with and without attention deficit hyperactivity disorder: misuse, cognitive impact, and adverse effects

Abstract

Prescription stimulants are often used to treat attention deficit hyperactivity disorder ( ADHD ). Drugs like methylphenidate (Ritalin, Concerta), dextroamphetamine (Dexedrine), and dextroamphetamine‐amphetamine (Adderall) help people with ADHD feel more focused. However, misuse of stimulants by ADHD and nonaffected individuals has dramatically increased over recent years based on students' misconceptions or simple lack of knowledge of associated risks. In this review, we discuss recent advances in the use and increasing misuse of prescription stimulants among high school and college students and athletes. Given the widespread belief that stimulants enhance performance, there are in fact only a few studies reporting the cognitive enhancing effects of stimulants in ADHD and nonaffected individuals. Student athletes should be apprised of the very serious consequences that can emerge when stimulants are used to improve sports performance. Moreover, misuse of stimulants is associated with dangers including psychosis, myocardial infarction, cardiomyopathy, and even sudden death. As ADHD medications are prescribed for long‐term treatment, there is a need for long‐term safety studies and education on the health risks associated with misuse is imperative.

Shown for reading. Its publisher allows quoting it, not republishing it.

References 139

1. 1.

   Advokat C. What are the cognitive effects of stimulant medications? Emphasis on adults with attention-deficit/hyperactivity disorder (ADHD). Neurosci. Biobehav. Rev. 2010;34:1256-1266.

   Not in our library10.1016/j.neubiorev.2010.03.006

2. 2.

   Advokat CD, Guidry MS, Martino BA. Licit and illicit use of medications for attention deficit hyperactivity disorder in undergraduate college students. J. Am. Coll. Health. 2008;56:601-607.

   Not in our library10.3200/jach.56.6.601-606

3. 3.

   Alsidawi S, Muth J, Wilkin J. Adderall induced inverted-Takotsubo cardiomyopathy. Catheter. Cardiovasc. Interv. 2011;78:910-913.

   Not in our library10.1002/ccd.23036

4. 4.

   Amariles P. A comprehensive literature search: drugs as possible triggers of Takotsubo cardiomyopathy. Curr. Clin. Pharmacol. 2011;6:1-11.

   Not in our library10.2174/157488411794941340

5. 5.

   DSM-IV-TR. 2000.

   Not in our library10.1176/appi.ps.51.10.1299

6. 6.

   ADHD exemptions on rise in MLB. 2009.

   Not in our library

7. 7.

   Barch DM, Carter CS. Amphetamine improves cognitive function in medicated individuals with schizophrenia and in healthy volunteers. Schizophrenia Res. 2005;77:43-58.

   Not in our library10.1016/j.schres.2004.12.019

8. 8.

   Barkley RA, Cunningham CE. Do stimulant drugs improve the academic performance of hyperkinetic children? A review of outcome studies. Clin. Pediatr. (Phila.). 1978;17:85-92.

   Not in our library10.1177/000992287801700112

9. 9.

   Barrett SP, Darredeau C, Brody LK, Pihl RO. Characteristics of methylphenidate misuse in a university student sample. Can. J. Psychiatry. 2005;50:457-461.

   Not in our library10.1177/070674370505000805

10. 10.

    Biederman J, Monuteaux MC, Mick E, Spencer T, Wilens TE, Silva JM, et al. Young adult outcome of attention deficit hyperactivity disorder: a controlled 10 year prospective follow-up study. Psychol. Med. 2006;36:167-179.

    Not in our library10.1017/s0033291705006410

11. 11.

    Biederman J, Petty CR, Fried R, Kaiser R, Dolan CR, Schoenfeld S, et al. Educational and occupational underattainment in adults with attention-deficit/hyperactivity disorder: a controlled study. J. Clin. Psychiatry. 2008a;69:1217-1222.

    Not in our library10.4088/jcp.v69n0803

12. 12.

    Biederman J, Seidman LJ, Petty CR, Fried R, Doyle AE, Cohen DR, et al. Effects of stimulant medication on neuropsychological functioning in young adults with attention deficit/hyperactivity disorder. J. Clin. Psychiatry. 2008b;69:1150-1156.

    Not in our library10.4088/jcp.v69n0715

13. 13.

    Biederman J, Fried R, Petty CR, Henin A, Wozniak J, Corkum L, et al. Examining the association between stimulant treatment and cognitive outcomes across the life cycle of adults with attention-deficit/hyperactivity disorder: a controlled cross-sectional study. J. Nerv. Ment. Dis. 2012;200:69-75.

    Not in our library10.1097/nmd.0b013e31823e55ef

14. 14.

    Bloom B, Cohen RA. Summary health statistics for U.S. children: National Health Interview Survey, 2006. Statistics VH. 2007;234:1-79.

    Not in our library

15. 15.

    Bogle KE, Smith BH. Illcit methylphenidate use: a review of prevalence, availability, pharmacology, and consequences. Curr. Drug Abuse Rev. 2009;2:157-176.

    Not in our library10.2174/1874473710902020157

16. 16.

    Bray CL, Cahill KS, Oshier JT, Peden CS, Theriaque DW, Flotte TR, et al. Methylphenidate does not improve cognitive function in healthy sleep-deprived young adults. J. Invest. Med. 2004;52:192-201.

    Not in our library10.1136/jim-52-03-34

17. 17.

    Breitenstein C, Wailke S, Bushuven S, Kamping S, Zwitserlood P, Ringelstein EB, et al. D-amphetamine boosts language learning independent of its cardiovascular and motor arousing effects. Neuropsychopharmacology. 2004;29:1704-1714.

    Not in our library10.1038/sj.npp.1300464

18. 18.

    Breitenstein C, Floel A, Korsukewitz C, Waike S, Bushuven S, Knecht S. A shift paradigm: from noradrenergic to dopaminergic modulation of learning? J. Neurol. Sci. 2006;248:42-47.

    Not in our library10.1016/j.jns.2006.05.012

19. 19.

    Brignell CM, Rosenthal J, Curran HV. Pharmacological manipulations of arousal and memory for emotional material: effects of a single dose of methylphenidate or lorazepam. J. Psychopharmacol. 2007;21:673-683.

    Not in our library10.1177/0269881107077351

20. 20.

    Brown RT, Amler RW, Freeman WS, Perrin JM, Stein MT, Feldman HM, et al. Treatment of attention-deficit/hyperactivity disorder: overview of the evidence. Pediatrics. 2005;115:e749-e757.

    Not in our library10.1542/peds.2004-2560

21. 21.

    Brumaghim JT, Klormart R. Methylphenidate's effects on paired-association learning and event-related potentials of young adults. Psychophysiology. 1998;35:73-85.

    Not in our library

22. 22.

    Burns JT, House RF, Fensch FC, Miller JG. Effects of magnesium pemoline and dextroamphetamine on human learning. Science. 1967;155:849-851.

    Not in our library10.1126/science.155.3764.849

23. 23.

    Callaway E. Presidential address. 1982: the pharmacology of human information processing. Psychophysiology. 1983;20:359-370.

    Not in our library10.1111/j.1469-8986.1983.tb00915.x

24. 24.

    Camp-Bruno JA, Herting RL. Cognitive effects of milacemide and methylphenidate in healthy young adults. Psychopharmacology. 1994;115:46-52.

    Not in our library10.1007/bf02244750

25. 25.

    Mental health in the United States. Prevalence of diagnosis and medication treatment for attention-deficit/hyperactivity disorder – United States, 2003. MMWR Morb. Mortal. Wkly. Rep. 2005a;54:842-847.

    Not in our library

26. 26.

    Prevalence of diagnosis and medication treatment for attention deficit/hyperactivity disorder – United States, 2003. MMWR Morbid. Mortal. Wkly. Rep. 2005b;54:842-847.

    Not in our library

27. 27.

    Increasing prevalence of parent-reported attention-deficit/hyperactivity disorder among children – United States, 2003 and 2007. MMWR Morb. Mortal. Wkly. Rep. 2010;59:1439-1443.

    Not in our library

28. 28.

    Chen JP. Methamphetamine-associated acute myocardial infarction and cardiogenic shock with normal coronary arteries: refractory global coronary microvascular spasm. J. Invasive Cardiol. 2007;19:E89-E92.

    Not in our library

29. 29.

    Clatworthy PL, Lewis SJ, Brichard L, Hong YT, Izquierdo D, Clark L, et al. Dopamine release in dissociable striatal subregions predicts the different effects of oral methylphenidate on reversal learning and spatial working memory. J. Neurosci. 2009;29:4690-4696.

    Not in our library10.1523/jneurosci.3266-08.2009

30. 30.

    Cooper NJ, Keage H, Hermens D, Williams LM, Debrota D, Clark CR. The dose-dependent effect of methylphenidate on performance, cognition, and psychophysiology. J. Integrative Neurosci. 2005;4:123-144.

    Not in our library10.1142/s0219635205000744

31. 31.

    Cooper WO, Habel LA, Sox CM, Chan KA, Arbogast PG, Cheetham TC, et al. ADHD drugs and serious cardiovascular events in children and young adults. N. Engl. J. Med. 2011;365:1896-1904.

    Not in our library10.1056/nejmoa1110212

32. 32.

    2008.

    Not in our library

33. 33.

    Dodds CM, Muller U, Clark L, van Loon A, Cools R, Robbins TW. Methylphenidate has differential effects on blood oxygenation level-dependent signal related to cognitive subprocesses of reversal learning. J. Neurosci. 2008;28:5976-5982.

    Not in our library10.1523/jneurosci.1153-08.2008

34. 34.

    Dopheide JA, Pliszka SR. Attention-deficit-hyperactivity disorder: an update. Pharmacotherapy. 2009;29:656-679.

    Not in our library10.1592/phco.29.6.656

35. 35.

    Elia J, Ambrosini PJ, Rapoport JL. Treatment of attention-deficit-hyperactivity disorder. N. Engl. J. Med. 1999;340:780-788.

    Not in our library10.1056/nejm199903113401007

36. 36.

    Elliott R, Sahakian BJ, Matthews K, Bannerjea A, Rimmer J, Robbins TW. Effects of methylphenidate on spatial working memory and planning in healthy young adults. Psychopharmacology. 1997;131:196-206.

    Not in our library10.1007/s002130050284

37. 37.

    Meeting highlights from the committee for medicinal products for human use, 16–19 July 2007. 2007.

    Not in our library

38. 38.

    Farah MJ, Halmm C, Sankoorikal G, Smith ME, Chatterjee A. When we enhance cognition with Adderall, do we sacrifice creativity? A preliminary study. Psychopharmacology. 2009;202:541-547.

    Not in our library10.1007/s00213-008-1369-3

39. 39.

    Faraone SV, Glatt SJ. A comparison of the efficacy of medications for adult attention-deficit/hyperactivity disorder using meta-analysis of effect sizes. J. Clin. Psychiatry. 2010;71:754-763.

    Not in our library10.4088/jcp.08m04902pur

40. 40.

    Faraone SV, Biederman J, Jetton JG, Tsuang MT. Attention deficit disorder and conduct disorder: longitudinal evidence for a familial subtype. Psychol. Med. 1997;27:291-300.

    Not in our library10.1017/s0033291796004515

41. 41.

    Faraone SV, Sergeant J, Gillberg C, Biederman J. The worldwide prevalence of ADHD: is it an American condition? World Psychiatry. 2007;2:104-113.

    Not in our library

42. 42.

    Fillmore MT, Kelly TH, Martin CA. Effects of d-amphetamine in human models of information processing and inhibitory control. Drug Alcohol Dep. 2005;77:151-159.

    Not in our library10.1016/j.drugalcdep.2004.07.013

43. 43.

    Fitzpatrick P, Klorman R, Brumaghim JT, Keefover RW. Effects of methylphenidate on stimulus evaluation and response processes: evidence from performance and event-related potentials. Psychophysiology. 1988;25:292-304.

    Not in our library10.1111/j.1469-8986.1988.tb01245.x

44. 44.

    Fleming K, Bigelow LB, Weinberger DR, Goldberg TE. Neuropsychological effects of amphetamine may correlate with personality characteristics. Psychopharmacol. Bull. 1995;31:357-362.

    Not in our library

45. 45.

    Gandhi PJ, Ezeala GU, Luyen TT, Tu TC, Tran MT. Myocardial infarction in an adolescent taking Adderall. Am. J. Health Syst. Pharm. 2005;62:1494-1497.

    Not in our library10.2146/ajhp040220

46. 46.

    Greydanus DE, Strasburger VC. Adolescent medicine. Prim. Care. 2006;33:xiii-xviii.

    Not in our library10.1016/j.pop.2006.02.006

47. 47.

    Gualtieri CT, Johnson LG. Medications do not necessarily normalize cognition in ADHD patients. J. Atten. Disord. 2008;11:459-469.

    Not in our library10.1177/1087054707305314

48. 48.

    Habel LA, Cooper WO, Sox CM, Chan KA, Fireman BH, Arbogast PG, et al. ADHD medications and risk of serious cardiovascular events in young and middle-aged adults. JAMA. 2011;306:2673-2683.

    Not in our library10.1001/jama.2011.1830

49. 49.

    Harris S. 2009.

    Not in our library

50. 50.

    Herman L, Shtayermman O, Aksnes B, Anzalone M, Cormerals A, Liodice C. The use of prescription stimulants to enhance academic performance among college students in health care programs. J. Physician Assist. Educ. 2011;22:15-22.

    Not in our library10.1097/01367895-201122040-00003

51. 51.

    Hester R, Nandam LS, O'Connell RG, Wagner J, Strudwick M, Nathan PJ, et al. Neurochemical enhancement of conscious error awareness. J. Neurosci. 2012;32:2619-2627.

    Not in our library10.1523/jneurosci.4052-11.2012

52. 52.

    Horrigan JP. Present and future pharacotherapeutic options for adult attention deficit/hyperactivity disorder. Exp. Opin. Psychopharmacol. 2001;2:573-586.

    Not in our library10.1517/14656566.2.4.573

53. 53.

    Hurst PM, Radlow R, Chubb NC, Bagley SK. Effects of D-amphetamine on acquisition, persistence, and recall. Am. J. Psychol. 1969;82:307-319.

    Not in our library

54. 54.

    Jacobs A. The Adderall advantage. The New York Times. 2005.

    Not in our library

55. 55.

    Jensen PS, Arnold LE, Swanson JM, Vitiello B, Abikoff HB, Greenhill LL, et al. 3-year follow-up of the NIMH MTA study. J. Am. Acad. Child Adolesc. Psychiatry. 2007;46:989-1002.

    Not in our library10.1097/chi.0b013e3180686d48

56. 56.

    Jiao X, Velez S, Ringstad J, Eyma V, Miller D, Bleiberg M. Myocardial infarction associated with Adderall XR and alcohol use in a young man. J. Am. Board Fam. Med. 2009;22:197-201.

    Not in our library10.3122/jabfm.2009.02.080003

57. 57.

    Johnston LD, O'Malley PM, Bachman JG, Schulenberg JE. Monitoring the future: national survey results on drug use, 1975–2003. Abuse. 2004;10-12.

    Not in our library

58. 58.

    Kadison R. Getting an edge – use of stimulants and antidepressants in college. N. Engl. J. Med. 2005;353:1089-1091.

    Not in our library10.1056/nejmp058047

59. 59.

    Kennedy RS, Odenheimer RC, Baltzley DR, Dunlap WP, Wood CD. Differential effects of scopolamine and amphetamine on microcomputer-based performance tests. Aviat. Space Environ. Med. 1990;61:615-621.

    Not in our library

60. 60.

    Kessler RC, Adler L, Barkley R, Biederman J, Conners CK, Demler O, et al. The prevalence and correlates of adult ADHD in the United Stated: results from the national comorbidity survey replication. Am. J. Psychiatry. 2006;163:716-723.

    Not in our library10.1176/appi.ajp.163.4.716

61. 61.

    Klorman R, Bauer LO, Coons HW, Lewis JL, Peloquin J, Perlmutter RA, et al. Enhancing effects of methylphenidate on normal young adults' cognitive processes. Psychopharmacol. Bull. 1984;20:3-9.

    Not in our library

62. 62.

    Koelega HS. Stimulant drugs and vigilance performance: a review. Psychopharmacology. 1993;111:1-16.

    Not in our library10.1007/bf02257400

63. 63.

    Kollins SH. Comparing the abuse potential of methylphenidate versus other stimulants: a review of available evidence and relevance to the ADHD patient. J. Clin. Psychol. 2003;64:14-18.

    Not in our library

64. 64.

    Kollins SH. ADHD, substance use disorder, and psychostimulant treatment current literature and treatment guidelines. J. Atten. Disord. 2008;12:115-125.

    Not in our library10.1177/1087054707311654

65. 65.

    Kollins SH, McClernon FJ, Fuemmeler BF. Association between smoking and attention-deficit/hyperactivity disorder symptoms in a population-based sample of children aged 9 through 16 years. J. Am. Acad. Child Adolesc. Psychiatry. 2005;62:1142-1431.

    Not in our library10.1001/archpsyc.62.10.1142

66. 66.

    Kuczenski R, Segal DS. Effects of methylphenidate on extracellular dopamine, serotonin, and norepinephrine: comparison with amphetamine. J. Neurochem. 1997;68:2032-2037.

    Not in our library10.1046/j.1471-4159.1997.68052032.x

67. 67.

    Kumari V, Corr PJ, Mulligan OF, Cotter PA, Checkley SA, Gray IA. Effects of acute administration of d-amphetamine and haloperidol on procedural learning in man: a preliminary study. Psychopharmacology. 1997;129:271-276.

    Not in our library10.1007/s002130050190

68. 68.

    Kutcher JS. Treatment of attention-deficit hyperactivity disorder in athletes. Curr. Sports Med. Rep. 2011;10:32-36.

    Not in our library10.1249/jsr.0b013e3182091d79

69. 69.

    Looby A, Earleywine M. Expectation to receive methylphenidate enhances subjective arousal but not cognitive performance. Exp. Clin. Psychopharmacol. 2011;19:433-444.

    Not in our library10.1037/a0025252

70. 70.

    Lord S, Downs G, Furlaw P, Chaudhurl A, Silverstein A, Gammaitoni A, et al. Nonmedical use of prescription opiods and stimulants among student pharmacists. J. Am. Pharm. Assoc. 2003;49:519-528.

    Not in our library10.1331/japha.2009.08027

71. 71.

    Low KG, Gendaszek AE. Illicit use of psychostimulants among college students: a preliminary study. Psychol. Health Med. 2002;7:283-287.

    Not in our library

72. 72.

    Makris AP, Rush CR, Frederich RC, Taylor AC, Kelly TH. Behavioral and subjective effects of d-ampetamine and modafinil in healthy adults. Exp. Clin. Psychopharmacol. 2007;15:123-133.

    Not in our library10.1037/1064-1297.15.2.123

73. 73.

    Masand P, Pickett P, Murray GB. Psychostimulants for secondary depression in medical illness. Psychosomatics. 1991;32:203-208.

    Not in our library10.1016/s0033-3182(91)72093-8

74. 74.

    Mattay VS, Berman KF, Ostrem JL, Esposito G, Van Horn JD, Bigelow LB. Dextroamphetamine enhances “neural network-specific” physiological signals: a positron emission tomography rCBF study. J. Neurosci. 1996;16:4816-4822.

    Not in our library10.1523/jneurosci.16-15-04816.1996

75. 75.

    Mattay VS, Callicott JH, Bertolino A, Heaton I, Frank JA, Coppola R, et al. Effects of dextroamphetamine on cognitive performance and cortical activation. NeuroImage. 2000;12:268-275.

    Not in our library10.1006/nimg.2000.0610

76. 76.

    Mattay VS, Goldberg TE, Fera F, Hariri AR, Tessitore A, Egan MF, et al. Catechol O-methyltransferase val158-met genotype and individual variation in the brain response to amphetamine. Proc. Natl. Am. Sci. USA. 2003;100:6186-6191.

    Not in our library10.1073/pnas.0931309100

77. 77.

    McCabe SE, Boyd CJ. Sources of prescription drugs for illicit use. Addict. Behav. 2005;30:1342-1350.

    Not in our library10.1016/j.addbeh.2005.01.012

78. 78.

    McCabe SE, Teter CJ, Boyd CJ. The use, misuse and diversion of prescription stimulants among middle and high school students. Subst. Use Misuse. 2004;39:1095-1116.

    Not in our library10.1081/ja-120038031

79. 79.

    McCabe SE, Knight JR, Teter CJ, Wechsler H. Nonmedical use of prescription stimulants among US college students: prevalence and correlates from a nationwide survey. Addiction. 2005;100:96-106.

    Not in our library10.1111/j.1360-0443.2005.00944.x

80. 80.

    McLaughlin L. Adderall: the whole story. 2011.

    Not in our library

81. 81.

    McNiel AD, Muzzin KB, DeWald JP, McCann AL, Schneiderman ED, Scofield J, et al. The nonmedical use of prescription stimulants among dental and dental hygiene students. J. Dental Edu. 2011;75:365-376.

    Not in our library

82. 82.

    Mehta MA, Owen AM, Sahakian BJ, Mavaddat N, Pickard JD, Robbins TW. Methylphenidate enhances working memory by modulating discrete frontal and parietal lobe regions in the human brain. J. Neurosci. 2000;20:RC65.

    Not in our library10.1523/jneurosci.20-06-j0004.2000

83. 83.

    Mintzer MZ, Griffiths RR. A triazolam/amphetamine dose-effect interaction study: dissociation of effects on memory versus arousal. Psychopharmacology. 2007;192:425-440.

    Not in our library10.1007/s00213-007-0726-y

84. 84.

    Misener VL, Luca P, Azeke O, Crosbie J, Waldman I, Tannock R, et al. Linkage of the dopamine receptor D1 gene to attention-deficit/hyperactivity disorder. Mol. Psychiatry. 2004;9:500-509.

    Not in our library10.1038/sj.mp.4001440

85. 85.

    Mitchell H. Faking ADHD Gets you into Harvard. The Daily Beast. 2012.

    Not in our library

86. 86.

    Molina BSG, Hinshaw SP, Swanson JM, Arnold LE, Vitiello B, Jensen PS, et al. The MTA at 8 years: prospective follow-up of children treated for combined type ADHD in the multisite study. J. Am. Acad. Child Adolesc. Psychiatry. 2009;48:484-500.

    Not in our library10.1097/chi.0b013e31819c23d0

87. 87.

    Murray JB. Psychophysiological aspects of amphetamine-methamphetamine abuse. J. Psychol. 1998;132:227-237.

    Not in our library10.1080/00223989809599162

88. 88.

    Musser CJ, Ahmann PA, Theye FW, Mundt P, Broste SK, Mueller-Rizner N. Stimulant use and the potential for abuse in Wisconsin as reported by school administrators and longitudinally followed children. J. Dev. Behav. Pediatr. 1998;19:187-192.

    Not in our library10.1097/00004703-199806000-00006

89. 89.

    Oken BS, Kishiyama SS, Salinsky MC. Pharmacologically induced changes in arousal: effects on behavioral and electrophysiologic measures of alertness and attention. Electroenceph Clin. Neurophysiol. 1995;95:359-371.

    Not in our library10.1016/0013-4694(95)00124-h

90. 90.

    Partridge BJ, Bell SK, Lucke JC, Yeates S, Hall WD. Smart drugs “as common as coffee”: media hype about neuroenhancement. PLoS One. 2011;6:e28416.

    Not in our library10.1371/journal.pone.0028416

91. 91.

    Pelham WE, McBurnett K, Harper GW, Milich R, Murphy DA, Clinton J, et al. Methylphenidate and baseball playing in ADHD children: who's on first? J. Consult. Clin. Psychol. 1990;58:130-133.

    Not in our library10.1037/0022-006x.58.1.130

92. 92.

    Piper BJ, Fraiman JB, Meyer JS. Repeated MDMA (“Ecstasy”) exposure in adolescent male rats alters temperature regulation, spontaneous motor activity, attention, and serotonin transporter binding. Dev. Psychobiol. 2005;47:145-157.

    Not in our library10.1002/dev.20085

93. 93.

    Polanczyk G, de Lima MS, Horta BL, Biederman J, Rohde LA. The worldwide prevalence of ADHD: a systematic review and metaregression analysis. Am. J. Psychiatry. 2007;164:942-948.

    Not in our library10.1176/ajp.2007.164.6.942

94. 94.

    Polchert SE, Morse RM. Pemoline abuse. JAMA. 1985;254:946-947.

    Not in our library

95. 95.

    Putukian M, Kreher JB, Coppell DB, Glazer JL, McKeag DB, White RD. Attention deficit hyperactivity disorder and the athlete: an American Medical Society for Sports Medicine position statement. Clin. J. Sport Med. 2011;21:392-401.

    Not in our library10.1097/jsm.0b013e3182262eb1

96. 96.

    Rabiner DL, Anastopoulos AD, Costello EJ, Hoyle RH, McCabe SE, Swartzweder HS. The misuse and diversion of prescribed ADHD medications by college students. J. Atten. Disord. 2009;13:144-153.

    Not in our library10.1177/1087054708320414

97. 97.

    Rapoport JL, Buchsbaum MS, Weingartner H, Zahn TP, Ludlow C, Mikkelsen EJ. Dextroamphetamine: cognitive and behavioral effects in normal and prepubertal boys. Science. 1978;199:560-563.

    Not in our library10.1126/science.341313

98. 98.

    Rasmussen P, Gillberg C. Natural outcome of ADHD with developmental coordination disorder at age 22 years: a controlled, longitudinal, community-based study. J. Am. Acad. Child Adolesc. Psychiatry. 2000;39:1424-1431.

    Not in our library10.1097/00004583-200011000-00017

99. 99.

    Rogers RD, Blackshaw AJ, Middleton HC, Matthews K, Hawtin K, Crowley C, et al. Tryptophan depletion impairs stimulus-reward learning while methylphenidate disrupts attentional control in healthy young adults: implications for the monoaminergic basis of impulsive behavior. Psychopharmacology. 1999;146:482-491.

    Not in our library10.1007/pl00005494

100. 100.

     Rosa-Neto P, Lou HC, Cumming P, Pryds O, Karrebaek H, Lunding J, et al. Methylphenidate-evoked changes in striatal dopamine correlate with inattention and impulsivity in adolescents with attention deficit hyperactivity/disorder. Neuroimage. 2005;25:868-876.

     Not in our library10.1016/j.neuroimage.2004.11.031

101. 101.

     Rosenthal E. Not acute myocardial infarction in a teenager due to Adderall XR. Pediatr. Cardiol. 2012;33:679.

     Not in our library10.1007/s00246-012-0243-6

102. 102.

     Sahakian BJ, Owen AM. Computerized assessment in neuropsychiatry using CANTAB: discussion paper. J. Royal Soc. Med. 1992;85:399-402.

     Not in our library

103. 103.

     Schelleman H, Bilker WB, Kimmel SE, Daniel GW, Newcomb C, Guevara JP, et al. Methylphenidate and risk of serious cardiovascular events in adults. Am. J. Psychiatry. 2012;169:178-185.

     Not in our library10.1176/appi.ajp.2011.11010125

104. 104.

     Schmedje JF, Oman CM, Letz R, Baker EL. Effects of scopolamine and dextroamphetamine on human performance. Aviation Space Environ. Med. 1988;59:407-410.

     Not in our library

105. 105.

     Schroeder SR, Mann-Koepke K, Gualtieri CT, Eckerman DA, Breese GR. Methylphenidate affects strategic choice behavior in normal adult humans. Pharmacol. Biochem. Behav. 1987;28:213-217.

     Not in our library10.1016/0091-3057(87)90217-6

106. 106.

     Schweitzer JB, Lee DO, Hanford RB, Zink CF, Ely TD, Tagamets MA, et al. Effect of methylphenidate on executive functioning in adults with attention deficit/hyperactivity disorder: normalization of behavior but not related brain activity. Biol. Psychiatry. 2004;56:597-606.

     Not in our library10.1016/j.biopsych.2004.07.011

107. 107.

     Sciutto MJ, Nolfi CJ, Bluhm C. Effects of child gender and symptom type on referrals for ADHD by elementary school teachers. J. Emotion Behav. Disord. 2004;12:247-253.

     Not in our library

108. 108.

     Servan-Schreiber D, Carter CS, Bruno RM, Cohen JD. Dopamine and the mechanisms of cognition: Part II. D-amphetamine effects in human subjects performing a selective attention task. Biol. Psychiatry. 1998;43:723-729.

     Not in our library10.1016/s0006-3223(97)00449-6

109. 109.

     Silber BY, Croft RJ, Papafotiou K, Stough C. The acute effects of d-amphetamine and methamphtetamine on attention and psychomotor performance. Psychopharmacology. 2006;187:154-169.

     Not in our library10.1007/s00213-006-0410-7

110. 110.

     Smith ME, Farah MJ. Are prescription stimulants “smart pills”? The epidemiology and cognitive neuroscience of prescription stimulant use by normal healthy individuals. Psychol. Bull. 2011;137:717-741.

     Not in our library10.1037/a0023825

111. 111.

     Soetens E, Dhooge R, Hueting J. Amphetamine enhances human-memory consolidation. Neurosci. Lett. 1993;161:9-12.

     Not in our library10.1016/0304-3940(93)90127-7

112. 112.

     Soetens E, Casaer S, Dhooge R, Hueting J. Effect of amphetamine on long-term retention of verbal material. Psychopharmacology. 1995;119:155-162.

     Not in our library10.1007/bf02246156

113. 113.

     Sroufe LA. Ritalin gone wrong. New York Times. 2012.

     Not in our library

114. 114.

     Strauss J, Lewis JL, Klorman R, Peloquin LJ, Perlmatter RA, Salzman LF. Effects of methylphenidate on young adults performance and event-related potentials in a vigilance and a paired-associates learning test. Psychophysiology. 1984;21:609-621.

     Not in our library10.1111/j.1469-8986.1984.tb00247.x

115. 115.

     Surles LK, May HJ, Garry JP. Adderall-induced psychosis in an adolescent. J. Am. Board Fam. Pract. 2002;15:498-500.

     Not in our library

116. 116.

     Sylvester AL, Agarwala B. Acute myocardial infarction in a teenager due to Adderall XR. Pediatr. Cardiol. 2012;33:155-157.

     Not in our library10.1007/s00246-011-0083-9

117. 117.

     Teter CJ, McCabe SE, Cranford JA, Boyd CJ, Guthrie SK. Prevalence and motivations for the illicit use of prescription stimulants in an undergraduate student sample. J. Am. Coll. Health. 2005;53:253-262.

     Not in our library10.3200/jach.53.6.253-262

118. 118.

     A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. Arch. Gen. Psychiatry. 1999;56:1073-1086.

     Not in our library10.1001/archpsyc.56.12.1073

119. 119.

     Tuttle JP, Scheurich NE, Ranseen J. Prevalence of ADHD diagnosis and nonmedical prescription stimulant use in medical students. Acad. Psychiatry. 2010;34:220-223.

     Not in our library10.1176/appi.ap.34.3.220

120. 120.

     Unrug A, Coenen A, van Luijtelaar G. Effects of the tranquilizer diazepam and the stimulant methylphenidate on alertness and memory. Neuropsychobiology. 1997;36:42-48.

     Not in our library10.1159/000119359

121. 121.

     Upadhyaya HP, Rose K, Wang W, O'Rourke K, Sullivan B, Deas D, et al. Attention-deficit/hyperactivity disorder, medication treatment, and substance use patterns among adolescents and young adults. J. Child Adolesc. Psychopharmacol. 2005;15:799-809.

     Not in our library10.1089/cap.2005.15.799

122. 122.

     Visser SN, Lesesne CA, Perou R. National estimates and factors associated with medication treatment for childhood attention-deficit/hyperactivity disorder. Pediatrics. 2012;119:S99-S107.

     Not in our library10.1542/peds.2006-2089o

123. 123.

     Vitiello B, Elliott GR, Swanson JM, Arnold LE, Hechtman L, Abikoff H, et al. Blood pressure and heart rate in the mulimodal treatment of attention deficit/hyperactivity disorder study over 10 years. Am. J. Psychiatry. 2011;169:167-177.

     Not in our library10.1176/appi.ajp.2011.10111705

124. 124.

     Volkow ND, Ding YS, Fowler JS, Wang GJ, Logan J, Gatley JS, et al. Is methylphenidate like cocaine? Studies on their pharmacokinetics and distribution in the human brain. Arch. Gen. Psychiatry. 1995;52:456-463.

     Not in our library10.1001/archpsyc.1995.03950180042006

125. 125.

     Volkow ND, Wang GJ, Newcorn J, Telang F, Solanto MV, Fowler JS, et al. Depressed dopamine activity in caudate and preliminary evidence of limbic involvement in adults with attention-deficit/hyperactivity disorder. Arch. Gen. Psychiatry. 2007;64:932-940.

     Not in our library10.1001/archpsyc.64.8.932

126. 126.

     Volkow ND, Wang GJ, Tomasi D, Kollins SH, Wigal TL, Newcorn JH, et al. Methylphenidate-elicited dopamine increases in ventral striatum are associated with long-term symptom improvement in adults with attention deficit hyperactivity disorder. J. Neurosci. 2012;32:841-849.

     Not in our library10.1523/jneurosci.4461-11.2012

127. 127.

     Ward AS, Kelly TH, Foltin RW, Fischman MW. Effects of d-amphetamine on task performance and social behavior of humans in a residential laboratory. Exp. Clin. Psychopharmacol. 1997;5:130-136.

     Not in our library10.1037//1064-1297.5.2.130

128. 128.

     Weitzner M. Manifest anxiety, amphetamine and performance. J. Psychol. 1965;60:71-79.

     Not in our library10.1080/00223980.1965.10545265

129. 129.

     Weyandt LL, DuPaul G. ADHD in college students. J. Atten. Disord. 2006;10:9-19.

     Not in our library10.1177/1087054705286061

130. 130.

     Wilens TE. Does the medicating ADHD increase or decrease the risk for later substance abuse? Rev. Bras. Psiquiatr. 2003;25:127-128.

     Not in our library10.1590/s1516-44462003000300001

131. 131.

     Wilens TE, Biederman J, Spencer TJ. Attention deficit/hyperactivity disorder across the lifespan. Annu. Rev. Med. 2002;53:113-131.

     Not in our library10.1146/annurev.med.53.082901.103945

132. 132.

     Wilens TE, Faraone S, Biederman J. Attention-deficit/hyperactivity disorder in adults. JAMA. 2004;292:619-623.

     Not in our library10.1001/jama.292.5.619

133. 133.

     Wilens TE, Adler LA, Adams J, Sgambati S, Rotrosen J, Sawtelle R, et al. Misuse and diversion of stimulants prescribed for ADHD: a systematic review of the literature. J. Am. Acad. Child Adolesc. Psychiatry. 2008;47:21-31.

     Not in our library10.1097/chi.0b013e31815a56f1

134. 134.

     Willett RA. The effect of a stimulant and a depressant drug on the serial rote learning of nonsense syllables. Psychopharmacologia. 1962;3:23-34.

     Not in our library10.1007/bf00413103

135. 135.

     Wise RA. Brain reward circuitry: insights from unsensed incentives. Neuron. 2002;36:229-240.

     Not in our library10.1016/s0896-6273(02)00965-0

136. 136.

     de Wit H, Crean J, Richards JB. Effects of d-amphetamine and ethanol on a measure of behavioral inhibition in humans. Behav. Neurosci. 2000;114:830-837.

     Not in our library10.1037//0735-7044.114.4.830

137. 137.

     de Wit H, Enggasser JL, Richards JB. Acute administration of d-amphetamine decreases impulsivity in healthy volunteers. Neuropsychopharmacology. 2002;27:813-825.

     Not in our library10.1016/s0893-133x(02)00343-3

138. 138.

     Zeeuws I, Soetens E. Verbal memory performance improved via an acute administration of D-amphetamine. Hum. Psychopharmacol. Clin. Exp. 2007;22:279-287.

     Not in our library10.1002/hup.848

139. 139.

     Zuvekas S, Vitiello B. Stimulant medication use in children: a 12-year perspective. Am. J. Psychiatry. 2011;169:160-166.

     Not in our library10.1176/appi.ajp.2011.11030387

Cited by papers we hold 1

• Associations of sleep disturbance with ADHD: implications for treatment · 2014
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.